Moderna, Inc. Net Income
Moderna, Inc. (MRNA) reported Net Income of -$782.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-07-31
- Moderna, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$782.00M.
- Moderna, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$1.34B.
- Moderna, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$826.00M.
- Moderna, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$200.00M, a 1638.46% decline year-over-year.
- Moderna, Inc. net income (loss) attributable to parent for fiscal 2025 was -$2.82B.
- Moderna, Inc. net income (loss) attributable to parent for fiscal 2024 was -$3.56B.
- Moderna, Inc. net income (loss) attributable to parent for fiscal 2023 was -$4.71B, a 156.37% decline from fiscal 2022.
- Moderna, Inc. net income (loss) attributable to parent for fiscal 2022 was $8.36B, a 31.47% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$782.00M 10-Q · filed 2026-07-31 | -$2.13B 10-Q · filed 2026-07-31 | -$2.95B derived: sum of 3 quarters · filed 2026-07-31 | -$3.15B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | -$1.34B 10-Q · filed 2026-05-01 | -$2.17B derived: sum of 2 quarters · filed 2026-05-01 | -$2.37B derived: sum of 3 quarters · filed 2026-05-01 | -$3.19B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | -$826.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.03B derived: sum of 2 quarters · filed 2026-02-20 | -$1.85B derived: sum of 3 quarters · filed 2026-07-31 | -$2.82B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | -$200.00M 10-Q · filed 2025-11-06 | -$1.02B derived: sum of 2 quarters · filed 2026-07-31 | -$2.00B 10-Q · filed 2025-11-06 | -$3.12B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | -$825.00M 10-Q · filed 2026-07-31 | -$1.80B 10-Q · filed 2026-07-31 | -$2.92B derived: sum of 3 quarters · filed 2026-07-31 | -$2.90B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | -$971.00M 10-Q · filed 2026-05-01 | -$2.09B derived: sum of 2 quarters · filed 2026-05-01 | -$2.08B derived: sum of 3 quarters · filed 2026-05-01 | -$3.36B derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$1.12B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.11B derived: sum of 2 quarters · filed 2026-02-20 | -$2.39B derived: sum of 3 quarters · filed 2026-02-20 | -$3.56B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $13.00M 10-Q · filed 2025-11-06 | -$1.27B derived: sum of 2 quarters · filed 2025-11-06 | -$2.44B 10-Q · filed 2025-11-06 | -$2.22B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | -$1.28B 10-Q · filed 2025-08-01 | -$2.45B 10-Q · filed 2025-08-01 | -$2.24B derived: sum of 3 quarters · filed 2026-02-20 | -$5.87B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | -$1.18B 10-Q · filed 2025-05-01 | -$958.00M derived: sum of 2 quarters · filed 2026-02-20 | -$4.59B derived: sum of 3 quarters · filed 2026-02-20 | -$5.97B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $217.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$3.41B derived: sum of 2 quarters · filed 2026-02-20 | -$4.79B derived: sum of 3 quarters · filed 2026-02-20 | -$4.71B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | -$3.63B 10-Q · filed 2024-11-07 | -$5.01B derived: sum of 2 quarters · filed 2024-11-07 | -$4.93B 10-Q · filed 2024-11-07 | -$3.47B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | -$1.38B 10-Q · filed 2024-08-01 | -$1.30B 10-Q · filed 2024-08-01 | $164.00M derived: sum of 3 quarters · filed 2025-02-21 | $1.21B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $79.00M 10-Q · filed 2024-05-02 | $1.54B derived: sum of 2 quarters · filed 2025-02-21 | $2.59B derived: sum of 3 quarters · filed 2025-02-21 | $4.78B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $1.47B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $2.51B derived: sum of 2 quarters · filed 2025-02-21 | $4.71B derived: sum of 3 quarters · filed 2025-02-21 | $8.36B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $1.04B 10-Q · filed 2023-11-03 | $3.24B derived: sum of 2 quarters · filed 2023-11-03 | $6.90B 10-Q · filed 2023-11-03 | $11.77B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | $2.20B 10-Q · filed 2023-08-03 | $5.85B 10-Q · filed 2023-08-03 | $10.72B derived: sum of 3 quarters · filed 2024-02-23 | $14.05B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $3.66B 10-Q · filed 2023-05-04 | $8.53B derived: sum of 2 quarters · filed 2024-02-23 | $11.86B derived: sum of 3 quarters · filed 2024-02-23 | $14.64B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $4.87B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $8.20B derived: sum of 2 quarters · filed 2024-02-23 | $10.98B derived: sum of 3 quarters · filed 2024-02-23 | $12.20B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $3.33B 10-Q · filed 2022-11-03 | $6.11B derived: sum of 2 quarters · filed 2022-11-03 | $7.33B 10-Q · filed 2022-11-03 | $7.06B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $2.78B 10-Q · filed 2022-08-03 | $4.00B 10-Q · filed 2022-08-03 | $3.73B derived: sum of 3 quarters · filed 2023-02-24 | $3.50B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $1.22B 10-Q · filed 2022-05-04 | $948.00M derived: sum of 2 quarters · filed 2023-02-24 | $715.00M derived: sum of 3 quarters · filed 2023-02-24 | $598.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | -$273.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | -$506.00M derived: sum of 2 quarters · filed 2023-02-24 | -$623.00M derived: sum of 3 quarters · filed 2023-02-24 | -$747.00M 10-K · filed 2023-02-24 | -$747.06M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | -$233.00M 10-Q · filed 2021-11-04 | -$233.64M 10-Q · filed 2020-10-30 | -$350.00M derived: sum of 2 quarters · filed 2021-11-04 | -$474.00M 10-Q · filed 2021-11-04 | -$474.58M 10-Q · filed 2020-10-30 | -$597.27M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | -$117.00M 10-Q · filed 2021-08-05 | -$116.71M 10-Q · filed 2020-08-06 | -$241.00M 10-Q · filed 2021-08-05 | -$240.94M 10-Q · filed 2020-08-06 | -$364.27M derived: sum of 3 quarters · filed 2022-02-25 | -$487.48M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | -$124.00M 10-Q · filed 2021-05-06 | -$124.23M 10-Q · filed 2020-05-07 | -$247.27M derived: sum of 2 quarters · filed 2022-02-25 | -$370.48M derived: sum of 3 quarters · filed 2022-02-25 | -$505.42M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$123.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$246.48M derived: sum of 2 quarters · filed 2022-02-25 | -$381.42M derived: sum of 3 quarters · filed 2022-02-25 | -$514.00M 10-K · filed 2022-02-25 | -$514.02M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | -$123.22M 10-Q · filed 2020-10-30 | -$123.19M 10-Q · filed 2019-11-06 | -$258.15M derived: sum of 2 quarters · filed 2020-10-30 | -$390.73M 10-Q · filed 2020-10-30 | -$390.90M 10-Q · filed 2019-11-06 | -$532.16M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-06-30 | -$134.94M 10-Q · filed 2020-08-06 | -$135.05M 10-Q · filed 2019-08-08 | -$267.52M 10-Q · filed 2020-08-06 | -$267.71M 10-Q · filed 2019-08-08 | -$408.94M derived: sum of 3 quarters · filed 2021-02-26 | -$489.27M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-03-31 | -$132.58M 10-Q · filed 2020-05-07 | -$132.66M 10-Q · filed 2019-05-09 | -$274.00M derived: sum of 2 quarters · filed 2021-02-26 | -$354.33M derived: sum of 3 quarters · filed 2021-02-26 | -$444.93M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | -$141.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$221.76M derived: sum of 2 quarters · filed 2021-02-26 | -$312.36M derived: sum of 3 quarters · filed 2021-02-26 | -$384.73M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | -$80.33M 10-Q · filed 2019-11-06 | -$170.93M derived: sum of 2 quarters · filed 2019-11-06 | -$243.31M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | -$90.60M 10-Q · filed 2019-08-08 | -$162.98M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | -$72.38M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$255.92M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | -$216.21M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |